Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma

医学 氟尿苷 奥沙利铂 吉西他滨 肝动脉灌注 内科学 实体瘤疗效评价标准 化疗 胃肠病学 临床研究阶段 癌症 外科 肿瘤科 氟尿嘧啶 结直肠癌
作者
Andrea Cercek,Thomas Boerner,Benjamin Tan,Joanne F. Chou,Mithat Gönen,Taryn Boucher,Haley Hauser,Richard Kinh Gian,Maeve A. Lowery,James J. Harding,Anna M. Varghese,Diane Reidy‐Lagunes,Leonard B. Saltz,Nikolaus Schultz,T. Peter Kingham,Michael I. D’Angelica,Ronald P. DeMatteo,Jeffrey A. Drebin,Peter J. Allen,Vinod P. Balachandran
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (1): 60-60 被引量:220
标识
DOI:10.1001/jamaoncol.2019.3718
摘要

IMPORTANCE: Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. OBJECTIVE: To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC. DESIGN, SETTING, AND PARTICIPANTS: A single-institution, phase 2 clinical trial including 38 patients was conducted with HAI floxuridine plus systemic gemcitabine and oxaliplatin in patients with unresectable IHC at Memorial Sloan Kettering Cancer Center between May 20, 2013, and June 27, 2019. A confirmatory phase 1/2 study using the same therapy was conducted during the same time period at Washington University in St Louis. Patients with histologically confirmed, unresectable IHC were eligible. Resectable metastatic disease to regional lymph nodes and prior systemic therapy were permitted. Patients with distant metastatic disease were excluded. INTERVENTIONS: Hepatic arterial infusion of floxuridine and systemic administration of gemcitabine and oxaliplatin. MAIN OUTCOMES AND MEASURES: The primary outcome was progression-free survival (PFS) of 80% at 6 months. RESULTS: For the phase 2 clinical trial at Memorial Sloan Kettering Cancer Center, 42 patients with unresectable IHC were included and, of these, 38 patients were treated (13 [34%] men; median [range] age at diagnosis, 64 [39-81] years). The median follow-up was 30.5 months. Twenty-two patients (58%) achieved a partial radiographic response, and 32 patients (84%) achieved disease control at 6 months. Four patients had sufficient response to undergo resection, and 1 patient had a complete pathologic response. The median PFS was 11.8 months (1-sided 90% CI, 11.1) with a 6-month PFS rate of 84.1% (90% CI, 74.8%-infinity), thereby meeting the primary end point (6-month PFS rate, 80%). The median OS was 25.0 months (95% CI, 20.6-not reached), and the 1-year OS rate was 89.5% (95% CI, 80.2%-99.8%). Patients with resectable regional lymph nodes (18 [47%]) showed no difference in OS compared with patients with node-negative disease (24-month OS: lymph node negative: 60%; 95% CI, 40%-91% vs lymph node positive: 50%; 95% CI, 30%-83%; P = .66). Four patients (11%) had grade 4 toxic effects requiring removal from the study (1 portal hypertension, 2 gastroduodenal artery aneurysms, 1 infection in the pump pocket). Subgroup analysis showed significant improvement in survival in patients with IDH1/2 mutated tumors (2-year OS, 90%; 95% CI, 73%-99%) vs wild-type (2-year OS, 33%; 95% CI, 18%-63%) (P = .01). In the Washington University in St Louis confirmatory cohort, 9 patients (90%) achieved disease control at 6 months; the most common grade 3 toxic effect was elevated results of liver function tests, and median PFS was 12.8 months (1-sided 90% CI, 6.4). CONCLUSIONS AND RELEVANCE: Hepatic arterial infusion plus systemic chemotherapy appears to be highly active and tolerable in patients with unresectable IHC; further evaluation is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
meta完成签到,获得积分10
5秒前
认真的可冥完成签到,获得积分10
5秒前
SnlyEng完成签到 ,获得积分10
14秒前
文文完成签到 ,获得积分10
15秒前
神也慕我谦姝完成签到,获得积分10
18秒前
钟原完成签到 ,获得积分10
21秒前
lzy完成签到 ,获得积分10
22秒前
28秒前
29秒前
2滴水完成签到,获得积分10
30秒前
Lee发布了新的文献求助10
31秒前
小静完成签到 ,获得积分10
33秒前
好好好发布了新的文献求助10
34秒前
周小篆完成签到,获得积分10
34秒前
Clover04的应助被科研通管家采纳,获得20
34秒前
Clover04的应助被科研通管家采纳,获得10
35秒前
Maestro_S的应助被科研通管家采纳,获得10
35秒前
胖胖橘完成签到 ,获得积分10
35秒前
cdercder的应助被科研通管家采纳,获得10
35秒前
亓雅丽完成签到 ,获得积分10
35秒前
36秒前
yk完成签到,获得积分10
43秒前
蒜蒜完成签到 ,获得积分10
44秒前
朱科源啊源完成签到 ,获得积分0
46秒前
香蕉觅云的应助被Cell采纳,获得10
49秒前
积极凌兰完成签到 ,获得积分10
51秒前
大气钥匙完成签到,获得积分10
57秒前
YHBBZ完成签到 ,获得积分10
58秒前
爱我不上火完成签到 ,获得积分10
58秒前
天宇完成签到,获得积分10
59秒前
vviruz完成签到,获得积分10
1分钟前
1分钟前
欧阳完成签到 ,获得积分10
1分钟前
Cell发布了新的文献求助10
1分钟前
两土日青发布了新的文献求助10
1分钟前
彭于晏的应助被好好好采纳,获得10
1分钟前
2026成功上岸完成签到 ,获得积分10
1分钟前
xia完成签到,获得积分10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852573
捐赠科研通 7789024
什么是DOI,文献DOI怎么找? 3436347
关于科研通互助平台的介绍 2560154
邀请新用户注册赠送积分活动 2482995